13F Holdings
中文EN

KALA KALA BIO, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1479419 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY72.9%
TTM EPS YoY196.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-345.3%
ROA-43.2%
ROIC (approx.)-1,688.4%
Asset turnover—

Leverage & solvency

Liabilities / assets14.5%
Debt / equity0.00x
Current ratio6.88x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.97x
Accruals ratio42.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0$0$3.89M$11.24M
R&D expense$18.78M$22.09M$18.59M$17.65M$11.52M
SG&A expense$23.63M$18.34M$20.57M$65.03M$105.06M
Operating income-$39.16M-$40.98M-$39.66M-$81.71M-$130.25M
Interest expense$3.28M$5.78M$5.81M$7.27M$8.38M
Income tax$0$0$0$0$0
Net income-$26.98M-$38.51M-$42.20M-$44.82M-$142.60M
EBITDA-$38.84M-$40.72M-$39.36M-$81.17M-$129.27M
EPS (basic)-3.31-10.15-17.35-29.48-108.32
EPS (diluted)-3.31-10.15-17.35-29.48-108.32
Weighted avg. shares (diluted)8.15M3.80M2.43M1.52M1.32M
Balance sheet
Cash & equivalents$7.56M$51.18M$50.90M$70.50M$92.14M
Receivables———$195,000$15.35M
Inventory————$8.64M
Current assets$9.49M$52.80M$52.87M$85.94M$124.37M
PP&E, net—$749,000$753,000$400,000$2.72M
Total assets$9.49M$55.48M$55.95M$86.82M$139.43M
Current liabilities$2.49M$16.96M$8.35M$25.68M$37.42M
Short-term debt—$10.34M—$5.00M—
Long-term debt—$20.10M$34.19M$37.94M$78.93M
Total debt—$30.44M$34.19M$42.94M$78.93M
Total liabilities$2.49M$43.15M$48.45M$67.85M$122.62M
Shareholders' equity$7.00M$12.33M$7.50M$18.97M$16.80M
Net debt—-$20.74M-$16.70M-$27.56M-$13.21M
Shares outstanding556,9956.09M2.76M1.71M1.32M
Cash flow statement
Operating cash flow-$31.99M-$29.38M-$27.93M-$78.91M-$108.23M
Investing cash flow-$15,000-$208,000-$429,000$62.72M$70.80M
Financing cash flow-$11.62M$29.88M$8.51M-$7.94M$42.55M
Depreciation & amortization$317,000$259,000$303,000$537,000$975,000
Stock-based compensation$7.00M$8.39M$7.46M$7.01M$16.09M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.